Table 3. Pairwise comparison of perioperative outcomes.
| Pairwise meta-analysis (mortality) | ||||
| Included Studies | Comparisons | OR (95% CI) | I2 | P |
| 7 studies | NTG vs. DILT | 0.83 (0.29, 2.41) | 0.00% | 1.000 |
| 5 studies | Placebo vs. NTG | 1.59 (0.31, 8.28) | 0.00% | 0.987 |
| 3 studies | Placebo vs. DILT | 4.00 (0.64, 25.15) | 0.00% | 0.574 |
| Pairwise meta-analysis (Cardiac protection) | ||||
| Included Studies | Comparisons | OR (95% CI) | I2 | P |
| post-MI | ||||
| 7 studies | NTG vs. DILT | 1.83 (0.77, 4.30) | 0.00% | 0.975 |
| 4 studies | Placebo vs. NTG | 2.24 (0.80, 6.28) | 0.00% | 0.596 |
| 1 studies | Placebo vs. DILT | 6.20 (0.27, 141.32) | - | - |
| TIE | ||||
| 5 studies | NTG vs. DILT | 1.67(0.99, 2.82) | 3.9% | 0.384 |
| 4 studies | Placebo vs. NTG | 1.42 (0.73, 2.75) | 0.0% | 0.707 |
| A-fib | ||||
| 7 studies | NTG vs. DILT | 2.67 (1.15, 6.24) | 62.20% | 0.014 |
| 2 studies | Placebo vs. DILT | 3.00 (1.18, 7.63) | 0.0% | 0.782 |
| Pairwise meta-analysis (Cardiac protection) | ||||
| Included Studies | Comparisons | MD (95% CI) | I2 | P |
| CK | ||||
| 1 study | NTG vs. Placebo | -36.00 (-232.18, 160.18) | NA | NA |
| 5 studies | DILT vs. NTG | -90.29 (-156.79, -23.79) | 0.00% | 0.691 |
| CKMB | ||||
| 6 studies | DILT vs. NTG | -12.47 (-18.33, -6.61) | 63.5% | 0.018 |
| 1 study | DILT vs. Placebo | -1.30 (-7.29,4.69) | NA | NA |
| Trop-T | ||||
| 4 Studies | DILT vs. NTG | -0.66 (-0.87, -0.44) | 0.0% | 0.42 |
| Pairwise meta-analysis (Cardiac function) | ||||
| Included Studies | Comparisons | OR (95% CI) | I2 | P |
| Inotrope | ||||
| 4 studies | NTG vs. DILT | 1.78 (0.78, 4.07) | 26.1% | 0.255 |
| 2 studies | Placebo vs. DILT | 0.19 (0.04, 0.73) | 0.0% | 0.419 |
| Pairwise meta-analysis (Cardiac function) | ||||
| Included Studies | Comparisons | MD (95% CI) | I2 | P |
| CCI | ||||
| 5 studies | DILT vs. NTG | -0.02 (-0.18, 0.13) | 21.3% | 0.279 |
| 2 studies | NTG vs. Placebo | 0.16 (-0.98, 0.42) | 69.2% | 0.072 |
| 1 study | DILT vs. Placebo | -0.10 (-0.62, 0.42) | NA | NA |
| HR | ||||
| 5 studies | NTG vs. Placebo | 2.54 (-6.22, 11.29) | 95.1% | 0.00 |
| 1 study | DILT vs. NTG | -13.00 (-23.56, -2.45) | NA | NA |
| 1 study | DILT vs. Placebo | -9.40 (-18.88, 0.08) | NA | NA |
| mBP (mmHg) | ||||
| 3 studies | NTG vs. Placebo | -2.61 (-11.70, 6.48) | 98.30% | 0.00 |
| 1 study | DILT vs. NTG | 2.00 (-7.92, 11.92) | NA | NA |
| 1 study | DILT vs. Placebo | 1.90 (-8.54, 12.34) | NA | NA |
| mPAP (mmHg) | ||||
| 2 studies | NTG vs. Placebo | -2.29 (-4.81, 0.23) | 29.40% | 0.23 |
| 1 study | DILT vs. NTG | -1.00 (-3.04, 1.04) | NA | NA |
| PAWP (mmHg) | ||||
| 4 studies | NTG vs. Placebo | -1.05 (-1.43, -0.70) | 0.0% | 0.64 |
| 1 study | DILT vs. NTG | -0.50 (-2.97, 1.97) | NA | NA |
| 1 study | DILT vs. Placebo | 0.80 (-1.84, 3.44) | NA | NA |
Note: OR greater than 1 favor the first treatment.